Iconovo AB (publ) develops inhaled medicinal products in Sweden. The company offers ICOres, a multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has a collaboration agreement with Lonza to develop spray-dried formulations of an intranasal biologic drug; and agreement with Kiox Pharma to develop an inhalable treatment for interstitial lung disease. The company was incorporated in 2013 and is headquartered in Lund, Sweden.
Frequently asked questions
What sector does Iconovo (ICO) operate in?
Iconovo belongs to the Healthcare sector and operates in the Medical Devices industry.
What is Iconovo (ICO) current stock price?
As of the latest data, Iconovo stock price is SEK 1.07, with a previous close of SEK 1.10. Iconovo lost -SEK 0.03 in the last trading session, representing a -2.73% loss.
What is Iconovo (ICO) current market capitalization?
Iconovo market cap is approximately 102.90 million.
What is Iconovo (ICO) Earnings Per Share (EPS)?
The trailing EPS is -SEK 0.71, and the forward EPS is -SEK 0.35.
What is Iconovo (ICO) EBITDA?
Iconovo EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -6.14 million.
Does Iconovo (ICO) pay dividends?
No. Iconovo does not pay a dividend.
What is Iconovo (ICO) beta (volatility) score?
Iconovo has a beta of 0.389, indicating lower volatility than the overall market.
